AUA 2017: A Comparison of Post-Cystectomy Recurrence and Survival in NAC-Responsive MIBC vs. High-Risk NMIBC Patients

Boston, MA (UroToday.com) The study reported here was done in patients who all received cystectomy. The objective was to compare post-surgical outcomes of high-risk non-muscle invasive bladder cancer (NMIBC) to patients who received neoadjuvant chemotherapy (NAC) who were downstaged and did not respond to NAC.

Patients who had NAC-responsive tumors had a better recurrence free and overall survival compared to high-risk NMIBC patients (p<0.02 and p<0.02). Tumors ≥2cm were independently associated with cancer recurrence. About one-quarter of the patients the in NMIBC had a distance recurrence (p<0.01). There was no difference in recurrence location in patients between the three groups. In conclusion this study showed better survival in NAC responsive MIBC than in NMIBC. 

This study further illustrate the importance of being able to identify response to chemotherapy and intravesical treatments to further improve patient survival from bladder cancer. In addition, this is a high-risk group where further characterization of disease biology would be a significant advance for bladder cancer. 

Presented By: Aaron Brant, Medical Student, Johns Hopkins University, Baltimore, MD

Written By:
Janet Baack Kukreja, MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX
Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Cancer Research, Department of Urology, UT MD Anderson Cancer Center, Houston TX

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe